ANGLE PLC has announced the granting of a European Patent for its CellKeep™ slide, with an imminent grant of the equivalent US patent application. The CellKeep slide is a result of a three-year development effort to address circulating tumor cell (CTC) loss in standard laboratory microscopy techniques. It eliminates over 70% of CTC loss experienced with standard techniques, improving assay sensitivity.

The Parsortix® system captures CTCs from blood, and the CellKeep slide reduces cell loss during the transfer of CTCs to the microscope slide, protecting the morphology of the harvested cells. This technique also concentrates CTCs into a smaller area on the slide, reducing costs and imaging time required for cell identification and analysis.

In analytical studies, the use of CellKeep slides significantly increased the identification of CTCs with higher sample positivity rates and better preservation of CTC morphology and clusters. ANGLE's Chief Executive Officer, Andrew Newland, stated that this technology advancement is significant for the CTC liquid biopsy field and a step towards enabling biomarker-guided precision medicine for people with cancer.

ANGLE's Chief Scientific Officer, Karen Miller, highlighted that the CellKeep slide enhances the capture of CTCs on slides and facilitates the evaluation of cancer cell biomarkers. This technology has the potential to capture other cell types from body fluids for subsequent analysis.

ANGLE's commercial businesses focus on diagnostic products and clinical services, including the Parsortix® system and associated consumables, as well as custom assay development and clinical trial sample testing for pharma. For further information, visit the ANGLE plc website.